Immunohistochemistry for the serial sections showed that GSK3β and p-GSK3βY216 were diffusely expressed and colocalized in the tumor cells and overexpressed in the invasive tumor cells of 8/15 (53%) pancreatic cancer patients (Fig. 1C). Here, GSK3B is linked to pancreatic neoplasm.